ROS1 Biomarkers

Turning Point Therapeutics' NDA Submission for Repotrectinib in Sight Based on Registrational Data

Nuvalent Begins Study of ROS1 Inhibitor in Advanced NSCLC, Solid Tumors

AnHeart Raises $61M in Oversubscribed Series B Financing Round

AnHeart Therapeutics Begins Phase II Taletrectinib Study in ROS1 Fusion-Positive Lung Cancer

AnHeart Therapeutics Begins Phase II Basket Trial of Taletrectinib in NTRK-Positive Solid Tumors

Zai Lab Begins Phase II Study of Repotrectinib in NSCLC, Solid Tumors in China

Nuvalent Raises $135M in Series B Funding

Turning Point Therapeutics to Discuss Repotrectinib NSCLC Data With FDA

Nuvalent Launches With $50 Million in Series A Funding

Daiichi Sankyo, AstraZeneca Begin Phase II Datopotamab Deruxtecan Trial in NSCLC

HitGen Outlicenses TRK/ROS1 Inhibitor to Baiyunshan for Development in Mainland China

COVID-19 Experience Spurs Cancer Research Community to Embrace Telemedicine-Enabled Trials

Turning Point's Repotrectinib Yields Promising Early Data in ROS1-, NTRK-Positive Cancers

Roche's Rozlytrek Garners Conditional Authorization in Europe for Cancers With NTRK, ROS1 Fusions

AnHeart Doses First ROS1 Fusion-Positive NSCLC Patient in Phase II Trial of Taletrectinib

Precision Oncology Trials Still Enroll Mostly White Patients Despite Initiatives, Calls to Diversify

Turning Point Therapeutics, Zai Lab Enter License Agreement for Repotrectinib in Greater China

UK's NICE Backs Roche's Rozlytrek for Patients With Advanced, ROS1-Positive Lung Cancer

AnHeart to Launch Phase II Taletrectinib Trials in Molecularly Defined Cancers